Literature DB >> 16585168

Targeted ablation of Par-4 reveals a cell type-specific susceptibility to apoptosis-inducing agents.

El Bachir Affar1, Margaret Po-shan Luke, Frédérique Gay, Dominica Calvo, Guangchao Sui, Robert S Weiss, En Li, Yang Shi.   

Abstract

The prostate apoptosis response-4 (Par-4) protein has been shown to function as an effector of cell death in response to various apoptotic stimuli, and down-regulation of this protein has been suggested to be a key event during tumorigenesis. Several studies suggest an essential function for the COOH-terminal leucine repeats/death domain of Par-4 in mediating apoptosis. We investigated the biological role of this domain in vivo by generating knock-out mice expressing a Par-4 mutant protein lacking the COOH terminus domain. We found that the Par-4 mutant mice are viable and fertile with no overt phenotype, thus excluding an essential role for the COOH terminus domain of Par-4 in embryogenesis and developmental apoptosis. To determine the requirement of Par-4 for apoptosis, we treated primary fibroblasts with various stimuli that trigger mitochondria and membrane receptor cell death pathways. Fibroblasts isolated from Par-4 mutant mice are as sensitive as the wild-type cells to these apoptosis-inducing agents. Similar effects were observed following RNA interference (RNAi)-mediated knockdown of Par-4 in these cells. In contrast, RNAi-mediated depletion of Par-4 in HeLa cells resulted in a significant inhibition of apoptosis induced by various proapoptotic agents. Taken together, our findings provide strong genetic evidence that the proapoptotic function of Par-4 is dependent on the cellular context and raise the possibility that alterations of Par-4 function may occur during carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16585168     DOI: 10.1158/0008-5472.CAN-05-0964

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

1.  Prostate apoptosis response 4 (Par-4), a novel substrate of caspase-3 during apoptosis activation.

Authors:  Parvesh Chaudhry; Mohan Singh; Sophie Parent; Eric Asselin
Journal:  Mol Cell Biol       Date:  2011-12-19       Impact factor: 4.272

2.  Par-4 overexpression impedes leukemogenesis in the Eµ-TCL1 leukemia model through downregulation of NF-κB signaling.

Authors:  J T Greene; Rajeswaran Mani; Rahul Ramaswamy; Frank Frissora; Max Yano; Kevan Zapolnik; Bonnie Harrington; Ronni Wasmuth; Minh Tran; Xiaokui Mo; Mary McKenna; Vivek M Rangnekar; John C Byrd; Subbarao Bondada; Natarajan Muthusamy
Journal:  Blood Adv       Date:  2019-04-23

3.  Prostate apoptosis response protein 4 sensitizes human colon cancer cells to chemotherapeutic 5-FU through mediation of an NF kappaB and microRNA network.

Authors:  Bi-Dar Wang; Christina Leah B Kline; Danielle M Pastor; Thomas L Olson; Bryan Frank; Truong Luu; Arun K Sharma; Gavin Robertson; Matthew T Weirauch; Steven R Patierno; Joshua M Stuart; Rosalyn B Irby; Norman H Lee
Journal:  Mol Cancer       Date:  2010-04-30       Impact factor: 27.401

Review 4.  Apoptosis and tumor resistance conferred by Par-4.

Authors:  Yanming Zhao; Vivek M Rangnekar
Journal:  Cancer Biol Ther       Date:  2008-12-08       Impact factor: 4.742

5.  Multimolecular complex of Par-4 and E2F1 binding to Smac promoter contributes to glutamate-induced apoptosis in human- bone mesenchymal stem cells.

Authors:  Chao Lu; Jie-Qing Chen; Guo-Ping Zhou; Sheng-Hua Wu; Ya-Fei Guan; Chuan-Shun Yuan
Journal:  Nucleic Acids Res       Date:  2008-07-26       Impact factor: 16.971

6.  Monoubiquitination of ASXLs controls the deubiquitinase activity of the tumor suppressor BAP1.

Authors:  Salima Daou; Haithem Barbour; Oumaima Ahmed; Louis Masclef; Caroline Baril; Nadine Sen Nkwe; Daméhan Tchelougou; Maxime Uriarte; Eric Bonneil; Derek Ceccarelli; Nazar Mashtalir; Mika Tanji; Jean-Yves Masson; Pierre Thibault; Frank Sicheri; Haining Yang; Michele Carbone; Marc Therrien; El Bachir Affar
Journal:  Nat Commun       Date:  2018-10-22       Impact factor: 14.919

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.